S11 Ep50: DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD
OncLive® On Air - Podcast tekijän mukaan OncLive® On Air
Drs Park and Curigliano discuss the DESTINY-Breast06 trial of T-DXd in patients with HER2-low or -ultralow, HR–positive, metastatic breast cancer.
